Tech Company Inital Public Offerings
Soligenix IPO
On 6/26/2013, Soligenix became a public company.
Transaction Overview
Company Name
Announced On
6/26/2013
Transaction Type
IPO
Amount
$7,100,000
Proceeds Purpose
The Company raised gross proceeds of approximately $7.1 million in the offering and intends to use the net proceeds from the offering to further develop its product candidates and for general working capital purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
29 Emmons Dr. B-10
Princeton, NJ 08540
USA
Princeton, NJ 08540
USA
Phone
Website
Email Address
Not Recorded
Overview
Soligenix, Inc. (OTCQB: SNGX) is a late-stage biopharmaceutical company committed to the development of life-saving therapeutics and vaccines. Soligenix has two areas of focus: 1) a therapeutics platform and 2) a biodefense platform to develop vaccines for military and civilian applications.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christopher Schaber
Chief Financial Officer
Karen Krumeich
Chief Medical Officer
Richard Straube
Chief Scientific Officer
Oreola Donini
Vice President
Christopher Cavalli
VP - Regulatory Affairs
Adam Rumage
Browse more venture capital transactions:
Prev: 6/26/2013: Tillster venture capital transaction
Next: 6/26/2013: LocalVox venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs